Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

JSFC Sistema reported for 9 months 2023 by IFRS

12/13/23 AFKS

Trust sold 93.6% of UWC shares to an unknown investor

12/13/23 UWGN

Samolet launched a digital ZPIF on commercial real estate for non-quals

12/13/23 SMLT

VK buys UFirst network of English language schools

12/13/23 VKCO

CarMoney has expanded its board of directors

12/12/23 CARM

Samolet has summarized the preliminary results of 2023

12/12/23 SMLT

Mosgorlombard extended the period for collecting applications for participation in the IPO

12/12/23 MGKL

Samolet developer buys bank

12/12/23 SMLT

Henderson expects to earn more than ₽2 billion in profits in 2023

12/12/23 HNFG

Henderson's 2023 dividend will be at least ₽25 per share

12/12/23 HNFG